<DOC>
	<DOCNO>NCT00303394</DOCNO>
	<brief_summary>Aim : To investigate therapeutic potential IL-1Ra type 2 diabetes . Rationale : Since major defect lead decrease b-cell mass type 2 diabetes increase apoptosis , therapeutic approach design arrest apoptosis could significant new development management . This approach might actually reverse disease degree rather palliate glycemia . Based current thinking , treatment IL-1Ra appear promising approach . The prospected effect block IL-1b-mediated glucotoxicity thereby prevent decline b-cell mass , together rapid restoration b-cell function . FDA approval IL-1Ra treatment rheumatoid arthritis occur base favourable tolerability profile .</brief_summary>
	<brief_title>Treatment Patients With Type 2 Diabetes With Interleukin-1 Antagonist</brief_title>
	<detailed_description>Methodology : This two-centre ( University Hospital , Zurich , Switzerland Steno Diabetes Center , Gentofte , Denmark ) study . 72 patient randomise accord double-blind , placebo-controlled protocol half patient treat IL-1Ra , half saline . The treatment period last 13 week . This time-period sufficient reversal functional glucotoxicity feasible term patient compliance . Whether 13 week treatment sufficient make significant change b-cell mass unpredictable . However , block b-cell apoptosis , new islet formation b-cell replication normal , may initiate enlargement b-cell mass , may progress beyond treatment period . Patient evaluation perform start 4 , 13 , 26 , 39 52 week . Following 13 week , patient fast plasma glucose level &gt; 8 mM glycosylated hemoglobin level ( HbA1c ) &gt; 8 % treated insulin . Insulin treatment initiate earlier avoid interference possible effect insulin primary outcome period large effect IL-1Ra expect . To assess effect IL-1Ra insulin sensitivity , subset 40 patient ( 20 IL-1Ra- 20 placebo-treated ) undergo euglycemic-hyperinsulinemic clamp well muscle fat biopsy start end treatment ( 13 week ) . The Ethics Committee centre already approve procedure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Age &gt; 20 Diabetes mellitus Type 2 ( American Diabetes Association criterion ) least 3 month duration HbA1c &gt; 7.5 % Bodymass index ( BMI ) &gt; 27 Positive GAD 65 IA2 antibody inclusion . HbA1c &gt; 12 % , polyuria thirst ( exclusion severely decompensated patient ) Cpeptide &lt; 400pmol/l ( basal ) Established antiinflammatory therapy ( includiung cortisone , NSAID , Cox2inhibitor ) . Low dose aspirin ( Â£ 100mg ) tolerate . CRP &gt; 30 mg/dl , fever , current treatment antibiotic , chronic granulomatous infection ( e.g . tuberculosis ) history screen chest Xray . Neutropenia anemia ( leucocyte count &lt; 2.0x109 /l , hemoglobin &lt; 11g/dl le &lt; 10g/dl female ) Pregnancy breastfeed . When appropriate ( fertile woman ) , anticonception last 3 month prior inclusion require . Severe liver renal disease ( AST ALT &gt; 3 time upper limit normal laboratory range , serum creatinine &gt; 130mM ) Ongoing malignant neoplasm Use investigational drug within 30 day enrollment study within 5 halflives investigational drug ( whichever longer ) Immunosuppressive treatment immunodeficient disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Type 2 Diabetes , IL-1 , inflammation , glucotoxicity , insulin</keyword>
</DOC>